Adjuvant antifibrotic therapy in a subpopulation of patients after TAVI

摘要

This invention concerns the field of personalised medicine, in particular the invention of personalised medical procedures for the treatment of patients undergoing or having undergone catheter-based aortic valve implantation (TAVI). More specifically, it concerns a procedure for identifying patients with aortic stenosis who are undergoing a TAVI that would benefit from treatment with an anti-fibrosis agent, as well as a procedure for monitoring the success of treatment of patients with aortic stenosis who have undergone a TAVI. Both procedures are common,that they determine the biomarker "myocardial fibrosis of equal to or more than 11% of the cross-section area of the myocardium". In addition, the invention concerns the use of a mass trichrome dye kit to determine the biomarker "myocardial fibrosis of more than 11% of the cross-sectional area of the myocardium" as a predictor of cardiovascular mortality in the treatment and/or prevention of patients with aortic stenosis; or Predictor of the success of treatment in the aftercare of patients with aortic stenosis,which have been subjected to a TAVI. Finally, the in vention concerns an anti-fibrosis agent used in the treatment and/or prevention of patients with aortic stenosis who are subject to TAVI; an anti-fibrosis agent used in the post-treatment of patients with aortic stenosis who have undergone TAVI; and a procedure to determine the optimal dose of hydralazine or dihydralazine in the anti-fibrosis treatment of a patient with aortic stenosis who is or has been TAVI-treated, each of which is characterised by myocardial fibrosis,which is equal to or higher than a clinically significant threshold of the cross-sectional area.